Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 119,56 Mrd USD | -243x | 2,14 | 463,15 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 13,7% Rialzo | Fai l’upgrade a Pro+ | |
Regeneron Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 112,17 Mrd USD | 25,7x | 1.039,96 USD | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,3% Rialzo | Fai l’upgrade a Pro+ | ||
Lonza Group AG | OTC Markets | Salute | Ricerca medica e biotecnologica | 46,06 Mrd USD | 72,6x | -1,39 | 63,99 USD | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,8% Rialzo | Fai l’upgrade a Pro+ | |
IQVIA Holdings | NYSE | Salute | Ricerca medica e biotecnologica | 43 Mrd USD | 30,1x | 0,95 | 236,28 USD | 2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 18,7% Rialzo | Fai l’upgrade a Pro+ | |
Alnylam | NASDAQ | Salute | Ricerca medica e biotecnologica | 35,33 Mrd USD | -471,8x | -5,17 | 274,57 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,2% Rialzo | Fai l’upgrade a Pro+ | |
argenx ADR | NASDAQ | Salute | Ricerca medica e biotecnologica | 31,96 Mrd USD | -154,3x | -3,06 | 524,58 USD | -4,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,5% Rialzo | Fai l’upgrade a Pro+ | |
BioNTech | NASDAQ | Salute | Ricerca medica e biotecnologica | 28,04 Mrd USD | -49,8x | 0,42 | 117,64 USD | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,3% Rialzo | Fai l’upgrade a Pro+ | |
Moderna | NASDAQ | Salute | Ricerca medica e biotecnologica | 24,66 Mrd USD | -4,2x | 0,01 | 63,93 USD | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
ICON PLC | NASDAQ | Salute | Ricerca medica e biotecnologica | 23,69 Mrd USD | 32,9x | 0,89 | 286,13 USD | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 30,8% Rialzo | Fai l’upgrade a Pro+ | |
BeiGene ADS | NASDAQ | Salute | Ricerca medica e biotecnologica | 21,40 Mrd USD | -39x | -0,59 | 212,53 USD | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 37,6% Rialzo | Fai l’upgrade a Pro+ | |
Summit Therapeutics PLC | NASDAQ | Salute | Ricerca medica e biotecnologica | 16,10 Mrd USD | -53,9x | -1,32 | 22,81 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
United Therapeutics | NASDAQ | Salute | Ricerca medica e biotecnologica | 15,92 Mrd USD | 15,5x | 0,64 | 357,72 USD | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,7% Ribasso | Fai l’upgrade a Pro+ | |
Genmab AS | NASDAQ | Salute | Ricerca medica e biotecnologica | 15,23 Mrd USD | 19x | 0,98 | 24,12 USD | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Vaxcyte | NASDAQ | Salute | Ricerca medica e biotecnologica | 13,83 Mrd USD | -24,5x | 0,7 | 111,44 USD | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 34,8% Rialzo | Fai l’upgrade a Pro+ | |
Insmed | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,53 Mrd USD | -13,4x | 5,14 | 72,87 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 18,9% Rialzo | Fai l’upgrade a Pro+ | |
EXACT Sciences | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,42 Mrd USD | -69,7x | -1,23 | 67,94 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,7% Rialzo | Fai l’upgrade a Pro+ | |
Bio-Techne | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,38 Mrd USD | 72,6x | -1,83 | 78,06 USD | 4,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,1% Rialzo | Fai l’upgrade a Pro+ | |
Sarepta | NASDAQ | Salute | Ricerca medica e biotecnologica | 11,93 Mrd USD | 250,8x | 2,45 | 124,84 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Neurocrine | NASDAQ | Salute | Ricerca medica e biotecnologica | 11,73 Mrd USD | 33,9x | 0,39 | 115,93 USD | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 48,4% Rialzo | Fai l’upgrade a Pro+ | |
Charles River Laboratories | NYSE | Salute | Ricerca medica e biotecnologica | 10,24 Mrd USD | 23,5x | -2,14 | 198,26 USD | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,5% Rialzo | Fai l’upgrade a Pro+ | |
Medpace Holdings | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,09 Mrd USD | 29,6x | 1,22 | 325,90 USD | 1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 29,5% Rialzo | Fai l’upgrade a Pro+ | |
Qiagen | NYSE | Salute | Ricerca medica e biotecnologica | 10 Mrd USD | 137,2x | -1,75 | 45,02 USD | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 15% Rialzo | Fai l’upgrade a Pro+ | |
Legend Bio | NASDAQ | Salute | Ricerca medica e biotecnologica | 8,57 Mrd USD | -29,7x | -0,61 | 46,85 USD | 7,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Tempus AI | NASDAQ | Salute | Ricerca medica e biotecnologica | 8,54 Mrd USD | -5,1x | 51,84 USD | 5,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -5,4% Ribasso | Fai l’upgrade a Pro+ | ||
Ascendis Pharma AS | NASDAQ | Salute | Ricerca medica e biotecnologica | 8,41 Mrd USD | -15,5x | -0,77 | 147,15 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 30,1% Rialzo | Fai l’upgrade a Pro+ | |
Exelixis | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,50 Mrd USD | 22,8x | 0,17 | 26,24 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,4% Rialzo | Fai l’upgrade a Pro+ | |
Revolution Med | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,32 Mrd USD | -12,3x | 1,08 | 43,86 USD | -2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 25,9% Rialzo | Fai l’upgrade a Pro+ | |
Halozyme | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,22 Mrd USD | 21,7x | 0,43 | 56,95 USD | 1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 9,2% Rialzo | Fai l’upgrade a Pro+ | |
Nuvalent | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,13 Mrd USD | -36,2x | 0,86 | 101,05 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 4,5% Rialzo | Fai l’upgrade a Pro+ | |
Viking Therapeutics Inc | NASDAQ | Salute | Ricerca medica e biotecnologica | 6,89 Mrd USD | -66,4x | 20,6 | 62,36 USD | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |